Elutia Inc Class A (ELUT)

Over the past six months, Elutia's stock has experienced significant events and volatility. In October 2025, Elutia closed the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million. In December 2025, the stock experienced a 28% price drop. In January 2026, Elutia announced the U.S. commercial launch of EluPro™. In February 2026, insider buying activity was observed. In March 2026, Elutia reported its fourth-quarter and full-year 2025 financial results, highlighting a strategic transformation towards its NXT-41x platform for breast reconstruction, initiated the NXT-41 regulatory process, and strengthened its balance sheet by repaying a $26.9 million loan facility.

There is no explicit information indicating specific demand seasonality for Elutia, Inc.'s products and services. Fluctuations in quarterly sales have been attributed to factors like changes in distribution models and customer order delays rather than clear seasonal patterns.

Elutia, Inc., formerly Aziyo Biologics, Inc., is a regenerative medicine company focused on developing and commercializing drug-eluting biomatrix products to improve compatibility between implantable medical devices and patients. Elutia operates within the Healthcare sector, specifically in the Medical Devices industry. The company has undergone a strategic shift, including the sale of its Orthobiologics business and the divestiture of its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation in October 2025. Currently, Elutia's primary focus is on its drug-eluting biomatrix platform and pipeline, with key products and development programs including SimpliDerm, NXT-41 and NXT-41x, and cardiovascular products.

Elutia Inc. is headquartered in Gaithersburg, Maryland, United States. The company serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors, primarily within the United States.

Elutia's brand reputation has been shaped by its strategic transformation and product developments. The company is recognized as a pioneer in drug-eluting biomatrix technologies. The full U.S. commercial launch of EluPro™ in January 2025 and the strategic divestiture of its BioEnvelope business to Boston Scientific for $88 million in October 2025 were positive events. Despite positive product developments, the company's stock performance has been volatile, with a significant decline over the past year.

Elutia, Inc. has a mixed ownership structure comprising institutional investors, insiders, and retail investors. Approximately 34.77% to 40.65% of the company's stock is held by institutional investors. Insiders own approximately 15.84% to 93.56% of the company's stock. Public companies and individual investors hold approximately 2.72% to 43.51% of the stock.